# MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

> **NCT00868595** · PHASE1 · COMPLETED · sponsor: **Bellicum Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Castrate Resistant Prostate Cancer (CRPC)

## Interventions

- **BIOLOGICAL:** BPX-101
- **DRUG:** AP1903

## Key facts

- **NCT ID:** NCT00868595
- **Lead sponsor:** Bellicum Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-07
- **Final completion:** 2012-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-10-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00868595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00868595, "MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00868595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*